BLACK DIAMOND THERAPEUTICS, INC. Lease, Cost
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Lease, Cost of -$54.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for the quarter ending 2026-06-30 was -$54.00K, a 120.30% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for the quarter ending 2026-03-31 was -$42.00K, a 113.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for the quarter ending 2025-12-31 was $200.00K, a 36.10% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for the quarter ending 2025-09-30 was $293.00K, a 7.86% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for fiscal 2025 was $1.08M, a 49.44% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for fiscal 2024 was $2.14M, a 46.47% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for fiscal 2023 was $4.00M, a 24.96% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. lease, cost for fiscal 2022 was $5.33M, a 22.15% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$54.00K 10-Q · filed 2026-08-05 | -$96.00K 10-Q · filed 2026-08-05 | $104.00K derived: sum of 3 quarters · filed 2026-08-05 | $397.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$42.00K 10-Q · filed 2026-05-07 | $158.00K derived: sum of 2 quarters · filed 2026-05-07 | $451.00K derived: sum of 3 quarters · filed 2026-05-07 | $717.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $493.00K derived: sum of 2 quarters · filed 2026-03-16 | $759.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.08M 10-K · filed 2026-03-16 |
| 2025-09-30 | $293.00K 10-Q · filed 2025-11-06 | $559.00K derived: sum of 2 quarters · filed 2026-08-05 | $882.00K 10-Q · filed 2025-11-06 | $1.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $266.00K 10-Q · filed 2026-08-05 | $589.00K 10-Q · filed 2026-08-05 | $902.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $323.00K 10-Q · filed 2026-05-07 | $636.00K derived: sum of 2 quarters · filed 2026-05-07 | $954.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.61M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $631.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.29M derived: sum of 3 quarters · filed 2026-03-16 | $2.14M 10-K · filed 2026-03-16 |
| 2024-09-30 | $318.00K 10-Q · filed 2025-11-06 | $975.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.83M 10-Q · filed 2025-11-06 | $2.79M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $657.00K 10-Q · filed 2025-08-07 | $1.51M 10-Q · filed 2025-08-07 | $2.47M derived: sum of 3 quarters · filed 2025-08-07 | $3.46M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $852.00K 10-Q · filed 2025-05-12 | $1.81M derived: sum of 2 quarters · filed 2025-05-12 | $2.80M derived: sum of 3 quarters · filed 2025-05-12 | $3.66M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.95M derived: sum of 2 quarters · filed 2025-03-06 | $2.81M derived: sum of 3 quarters · filed 2025-03-06 | $4.00M 10-K · filed 2025-03-06 |
| 2023-09-30 | $990.00K 10-Q · filed 2024-11-05 | $1.85M derived: sum of 2 quarters · filed 2024-11-05 | $3.04M 10-Q · filed 2024-11-05 | $4.40M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $856.00K 10-Q · filed 2024-08-06 | $2.05M 10-Q · filed 2024-08-06 | $3.41M derived: sum of 3 quarters · filed 2024-08-06 | $4.74M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.19M 10-Q · filed 2024-05-09 | $2.55M derived: sum of 2 quarters · filed 2024-05-09 | $3.89M derived: sum of 3 quarters · filed 2024-05-09 | $5.18M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.70M derived: sum of 2 quarters · filed 2024-03-12 | $3.99M derived: sum of 3 quarters · filed 2024-03-12 | $5.33M 10-K · filed 2024-03-12 |
| 2022-09-30 | $1.34M 10-Q · filed 2023-11-06 | $2.63M derived: sum of 2 quarters · filed 2023-11-06 | $3.97M 10-Q · filed 2023-11-06 | $5.28M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $1.30M 10-Q · filed 2023-08-11 | $2.63M 10-Q · filed 2023-08-11 | $3.94M derived: sum of 3 quarters · filed 2023-08-11 | $5.27M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $1.33M 10-Q · filed 2023-05-09 | $2.65M derived: sum of 2 quarters · filed 2023-05-09 | $3.97M derived: sum of 3 quarters · filed 2023-05-09 | $4.92M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.64M derived: sum of 2 quarters · filed 2023-03-09 | $3.58M derived: sum of 3 quarters · filed 2023-03-09 | $4.36M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.32M 10-Q · filed 2022-11-08 | $2.27M derived: sum of 2 quarters · filed 2022-11-08 | $3.05M 10-Q · filed 2022-11-08 | $3.74M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $944.00K 10-Q · filed 2022-08-09 | $1.73M 10-Q · filed 2022-08-09 | $2.41M derived: sum of 3 quarters · filed 2022-08-09 | $2.91M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $782.00K 10-Q · filed 2022-05-11 | $1.47M derived: sum of 2 quarters · filed 2022-05-11 | $1.96M derived: sum of 3 quarters · filed 2022-05-11 | $2.13M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $687.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.18M derived: sum of 2 quarters · filed 2022-03-17 | $1.35M derived: sum of 3 quarters · filed 2022-03-17 | $1.58M 10-K · filed 2022-03-17 |
| 2020-09-30 | $494.00K 10-Q · filed 2020-11-10 | $665.00K derived: sum of 2 quarters · filed 2020-11-10 | $893.00K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $171.00K 10-Q · filed 2020-08-11 | $399.00K 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $228.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |